Evolent Health (EVH) opened Q1 2026 with revenue of US$496.2 million, a basic EPS loss of US$0.24, and a net income loss of US$26.6 million, setting a clear tone for another quarter where growth and profitability are pulling in different directions. The company reported quarterly revenue of US$483.6 million in Q1 2025 and US$496.2 million in Q1 2026, while basic EPS over that span ranged from a loss of US$0.63 in Q1 2025 to a loss of US$0.24 in the latest quarter. This frames a results season where investors are weighing solid top line scale against margins that remain firmly in loss making territory.

See our full analysis for Evolent Health.

With the headline numbers on the table, the next step is to see how these results compare with the prevailing growth and risk narratives that have built around Evolent Health over the past year.

Losses stay heavy at US$533.8 million over the last year

• On a trailing twelve month basis to Q1 2026, Evolent Health booked a net loss of US$533.8 million on US$1.9b of revenue, with basic EPS at a loss of US$4.71.
• Consensus narrative expects long term margin improvement, yet the trailing figures show losses expanding over several years, so:
  • Analysts model revenue growth of 20.2% a year and profit margins eventually rising from a loss of 30.9% to 6.0%, while the latest twelve month net income is still deeply negative at US$533.8 million.
  • This contrast means any view that Evolent will reach US$196.3 million of earnings and US$1.97 EPS by around 2029 is heavily reliant on a shift that is not visible in the current loss profile.

Quarterly losses narrow from Q4’s US$429.1 million

• Q1 2026 net loss was US$26.6 million with basic EPS at a loss of US$0.24, compared with Q4 2025 where the loss was US$429.1 million and basic EPS loss was US$3.84 on slightly lower revenue of US$468.7 million.
• Bulls argue that operational changes and AI driven automation can steadily lift margins, and the step down in quarterly loss size ties into that view, yet it still leaves clear work to do:
  • Management initiatives like targeting higher automation and improving contract structures sit against a backdrop where trailing twelve month losses have grown at about 43.2% a year over five years.
  • For a bullish case that points to margins rising from a loss of 8.4% today to a 1.4% profit and earnings of US$46.7 million by around 2028, this quarter’s smaller loss is just an early data point rather than confirmation.

On these numbers, bulls point to improving loss levels while keeping an eye on whether margins really move toward their long term targets. 🐂 Evolent Health Bull Case

Low 0.3x P/S with no profitability in sight

• The stock trades on a P/S of 0.3x compared with 2.2x for the wider US Healthcare Services industry and 2.6x for peers, while the company is still unprofitable and is not expected to reach profitability within the next three years.
• Bears focus on this mix of low valuation and persistent losses, and the current financials give them several concrete points:
  • Trailing twelve month revenue has stepped down from US$2.6b in Q4 2024 to US$1.9b in Q1 2026, and losses over that window have scaled up from US$93.5 million to US$533.8 million.
  • With analysts not forecasting a return to profit in the next three years and share price volatility higher than the US market, a low P/S multiple alone does not counter the concern about earnings durability.

For anyone weighing that low multiple against the scale of ongoing losses, it helps to see how more cautious investors frame the downside case. 🐻 Evolent Health Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Evolent Health on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Conflicted by the mix of heavy losses and optimistic forecasts you have just read? Act quickly, review the key data points for yourself, then weigh up the 3 key rewards and 2 important warning signs

See What Else Is Out There

Evolent Health is working with heavy trailing twelve month losses of US$533.8 million, no clear path to profit and share price volatility above the broader US market.

If that mix of ongoing losses and volatility feels uncomfortable, balance your research by checking companies with steadier profiles using the 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.